Figure 2.

Pharmacodynamic analysis of vorinostat through transcription of BIM mRNA isoforms in PBMC. A, PBMC were harvested at baseline and 4 h after giving gefitinib and 200 mg (n = 3), 300 mg (n = 3), and 400 mg (n = 5) vorinostat on day 2 of cycle 1. RNA was purified from PBMC and mRNA expression of BIM exon 2A (representative of total BIM mRNA expression), exon 3 (representative of the inactive isoform of BIM mRNA), and exon 4 (representative of the proapoptotic isoform of BIM mRNA) is shown. B, BIM mRNA exon 3/exon 4 ratio. *P < .05 vs baseline. C, Change in BIM mRNA exon 3/exon 4 ratio before and 2 d after treatment with vorinostat and gefitinib. Bars indicate mean ± SD